• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

PeDRA Lists Systemics With Higher COVID-19 Risk

Dermatology TimesDermatology Times, Psoriasis Supplement, August 2021 (Vol. 42, Supp. 02)
Volume 42
Issue 2

Some systemic medications may have increased risk for patients during the COVID-19 era, according to a recent Pediatric Dermatology Research Alliance (PeDRA) statement.

According to a recent Pediatric Dermatology Research Alliance (PeDRA) statement, some systemic medications may have increased risk for patients during the COVID-19 era. The immunosuppressant medications listed below may carry a higher risk of infection than those considered more immunomodulating (eg, low-dose methotrexate, apremilast [Otezla; Amgen]. The risk of infection also varies among the biologic agents.

Immunosuppressant medications:

  • Small molecules
    • Corticosteroids (eg, prednisone, prednisolone, methylprednisolone)
    • Cyclosporine
    • Mycophenolate mofetil
    • Tacrolimus
    • Azathioprine
  • Biologics
    • Anti-CD20 (pan–B cell) rituximab [Rituxan; Genetech]
    • Tumor necrosis factor inhibitors (eg, etanercept [Enbrel; Amgen], adalimumab, infliximab [Avsola; Amgen]
    • IL-17 inhibitors (eg, secukinumab [Cosentyx; Novartis], ixeki-zumab [Taltz; Eli Lilly and Company]
    • IL-12/IL-23 inhibitor ustekinumab [Stelara; Janssen Pharmaceuticals]

It may be safer to continue rather than discontinue these or other medicines for children with moderate to severe skin disease, according to PeDRA. Providers should weigh whether the risk of a worsening skin condition when off the medicine is greater than the risk of COVID-19 infection and severe health consequences of an infection.

Source: PeDRA. General information for patients and caregivers about COVID-19. Updated May 11, 2020. Accessed June 24, 2021. General Information for Patients and Caregivers about COVID-19 (pedraresearch.org).

Reviewed June 30, 2021, for Dermatology Times® by Elaine Siegfried, MD, professor of pediatrics and dermatology at Saint Louis University Doisy College of Health Sciences and director of pediatric dermatology at Cardinal Glennon Children’s Hospital in St Louis, Missouri.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.